CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2017—Qiagen announced the European launch of its CE-IVD marked calreticulin mutation assay to aid in establishing the diagnosis of myeloproliferative neoplasms.
The ipsogen CALR RGQ PCR kit is intended for the detection of CALR mutations in genomic DNA from subjects suspected of myeloproliferative neoplasms. It enables identification of the two major CALR mutations, type 1 and type 2, and detects additional mutations in the CALR exon 9 region. The ipsogen CALR assay simplifies calreticulin testing by covering various relevant mutations in a real-time PCR-based assay to deliver multiple clinical results in less than one business day. The test runs on the company’s QIAsymphony and Rotor-Gene platforms, employing the CE-IVD marked Rotor-Gene Q MDx 5Plex HRM Platform real-time cycler. Maximum throughput flexibility is achieved by DNA sample processing from peripheral blood using either the manual QIAamp DSP DNA Blood Mini kit or the fully automated sample processing on the QIAsymphony SP instrument. The kit is highly synergistic with the CE-IVD marked ipsogen JAK2 RGQ PCR kit, Qiagen’s solution to detect the V617F mutation in the Janus kinase 2 (JAK2) gene, as CALR mutations can be detected from the same patient sample.
Qiagen, 240-686-7700